Colorectal Cancer

Jessica Paulus, ScD, discusses findings from a real-world, retrospective analysis of factors contributing to early-onset CRC.

Panelists discuss how dihydropyrimidine dehydrogenase testing remains controversial with institutions debating whether to implement universal pharmacogenomic testing given the challenges of standardization, genotype-phenotype correlation, and low incidence of severe deficiency.

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

The NCCN has added the Shield blood test and the ColoSense test to its colorectal cancer screening guidelines.

Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.

Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.

MK-1084 produced responses and was safe in KRAS G12C–mutated advanced colorectal cancer.

Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.

Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.

Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.

Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.

In the colorectal cancer space, the role of ctDNA can help reduce the use of certain therapies.

Cetuximab β was effective and safe in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.

CX-2051 elicited an overall response rate of 28% with manageable safety in heavily pretreated colorectal cancer.

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

Neoadjuvant dostarlimab led to an 82% clinical complete response and a 92% 2-year RFS rate, supporting nonoperative management in early-stage dMMR tumors.

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.